Following people with colorectal cancer to study markers linked to outcomes
Looks for tumor and blood markers tied to outcomes in adults with colorectal cancer.
Plain-language title generated from the registry record
Registry title: Prospective Multicenter Cohort Study of Clinical and Molecular Biomarkers in Colorectal Cancer
Key facts
- Where
- Bregenz, Feldkirch, Hohenems, and Rankweil, AustriaSee the 4 sites
Where in Austria
- Landeskrankenhaus BregenzBregenz, AustriaTaking people
- Landeskrankenhaus FeldkirchFeldkirch, AustriaTaking people
- Landeskrankenhaus HohenemsHohenems, AustriaNo longer taking part
- Landeskrankenhaus RankweilRankweil, AustriaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vorarlberg Institute for Vascular Investigation and Treatment
- Trial code
- NCT07913802
- Record updated
- 3 November 2026
- Original description
This prospective, multicenter observational study aims to identify clinical and molecular biomarkers associated with treatment response, disease recurrence, progression, and survival in patients with colorectal cancer (CRC).Read full original descriptionShow less
Prospective Cohort Study to Investigate Clinical Factors and Molecular Biomarkers Associated With Treatment Response and Disease Outcomes in Patients With Colorectal Cancer in Vorarlberg, Austria
This prospective, multicenter observational study aims to identify clinical and molecular biomarkers associated with treatment response, disease recurrence, progression, and survival in patients with colorectal cancer (CRC).
Approximately 200 adult patients undergoing surgical resection for CRC will be enrolled and followed for up to five years. Tumor tissue and blood samples will be collected for molecular analyses, and clinical data will be recorded longitudinally to investigate associations between biomarkers and disease outcomes.
All treatment decisions will follow standard clinical practice and will not be influenced by study participation.
Inclusion: Age ≥18 years; Histologically confirmed colorectal carcinoma; Planned surgical resection of the primary colorectal tumor; Written informed consent to participate in the study.
Exclusion: Known current alcohol and/or illicit drug abuse that, in the investigator's judgment, may compromise participant safety and/or compliance; Age <18 years; Pregnancy; Individuals held in custody by order of a court or public authority; Inability to understand and sign the informed consent form.